Rostafuroxin – 10 mg

Brand:
Cayman
CAS:
156722-18-8
Storage:
-20
UN-No:
Non-Hazardous - /

Rostafuroxin potently inhibits binding of endogenous ouabain to the Na+/K+ ATPase (IC50 = 1.7 µM) through the Src-epidermal growth factor receptor (EGFR)-dependent signaling pathway.{33528} This blocks the ouabain-dependent increase in Na+/K+ ATPase activity. In cultured renal cells where the Na+/K+ ATPase is upregulated or has increased activity, rostafuroxin normalizes mRNA levels and Na+/K+ ATPase activity.{33530} At very low doses (1 and 10 µg/kg for 5-6 weeks) in Milan-hypertensive rats, it decreased the development of hypertension.{33531} In a Phase II clinical study, rostafuroxin did not reduce blood pressure in human patients at doses of 0.05-5.0 mg/d.{33532}  

 

Out of stock

SKU: 21282 - Category:

Description

Prevents binding of endogenous ouabain to the Na+/K+ ATPase (IC50 = 1.7 µM)


Formal name: (3β,5β,14β)-21,23-epoxy-24-norchola-20,22-diene-3,14,17-triol

Synonyms:  PST 2238

Molecular weight: 374.5

CAS: 156722-18-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|ATPases||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Kidney & Renal Disease